Sort   by:  
 Page size 
MetabolomicsMicrobial Product Cocktails for Personalized Cancer Immunotherapy

The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective i...

2025-07-01 | MTBLS12666 | MetaboLights
MetabolomicsCirculating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
ModelsKronik2010 - Predicting Outcomes of Prostate Cancer Immunotherapyby Personalized Mathematical Models
Predicting Outcomes of Prostate Cancer Immunotherapyby Personalized Mathematical Models Natalie Kronik1¤, Yuri Kogan1, Moran Elishmereni1, Karin Halevi-Tobias1, Stanimir Vuk-Pavlovic ́2.,Zvia Agur1*.1Institute for Medical BioMathematics, Bene Ataroth, Israel,2College of Medicine, Mayo Clinic, Roche...
2020-01-13 | MODEL2001130003 | BioModels
Immuno-oncology 
ProteomicsProteogenomic Discovery of Neoantigens Facilitates Personalized Multi-antigen Targeted T cell Immunotherapy for Brain Tumors
Neoantigen discovery in pediatric brain tumors is hampered by their low mutational burden and scant tissue availability. We developed a low-input proteogenomic approach combining tumor DNA/RNA sequencing and mass spectrometry proteomics to identify tumor-restricted (neoantigen) peptides arising from...
ORGANISM(S): Homo sapiens (Human) 
2021-11-02 | PXD029082 | Pride
Lc-msms Medulloblastoma Pediatric brain tumors 
GenomicsMicrobial Product Cocktails for Personalized Cancer Immunotherapy
Microbial Product Cocktails for Personalized Cancer Immunotherapy
PRJNA1271468 | ENA
ProteomicsNeoDisc: A neoantigen discovery pipeline for the development of personalized cancer immunotherapy
The accurate identification and prioritization of antigenic peptides presented by class-I and -II human leukocyte antigens (HLA-I and -II) recognized by autologous T cells is crucial for the development of cancer immunotherapies. While several clinical neoantigen prediction pipelines are now publicl...
ORGANISM(S): Homo sapiens (Human) 
2024-08-30 | PXD047641 | Pride
Neoantigens Proteogenomics Prediction Immunopeptidomics Antigen discovery 
ProteomicsEx vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immun...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-06 | MSV000088992 | MassIVE
ProteomicsImmunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia
In recent years the clinical success of T cell-based immunotherapy approaches has revolutionized treatment of solid tumors and hematological malignancies. However, still some patients do not respond to available therapies at all, others for limited time only. A promising low side-effect approach is ...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024871 | Pride
Cll Hla Peptide warehouse Immunopeptidome 
GenomicsEndogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
PRJNA926630 | ENA
ProteomicsIndividualized proteogenomics reveals mutational landscape of melanoma patients in response to immunotherapy
Immune checkpoint inhibitors are used to restore or augment antitumor immune response and show great promise in treatment of melanoma and other types of cancers. However, only a relatively small percentage of patients are fully responsive to immune checkpoint inhibition, mostly due to tumor heteroge...
ORGANISM(S): Homo sapiens (Human) 
2022-02-16 | PXD028700 | Pride
Melanoma Mass spectrometry Proteogenomics Whole exome sequencing Immunotherapy 
Sort   by:  
 Page size